Beyond Cytotoxic Potency: Disposition Features Required to Design ADC Payload
Author:
Affiliation:
1. Clinical Pharmacology and Translational Sciences, Pfizer Oncology Division, Pfizer, Inc., Bothell, Washington 98021
Publisher
Informa UK Limited
Link
https://www.tandfonline.com/doi/pdf/10.1080/00498254.2024.2381139
Reference163 articles.
1. Advani A Coiffier B Czuczman MS Dreyling M Foran J Gine E Gisselbrecht C Ketterer N Nasta S Rohatiner A and others. (2010). Safety pharmacokinetics and preliminary clinical activity of inotuzumab ozogamicin a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 28 2085-93.
2. Ahn I Kang CS Han J. (2023). Where should siRNAs go: applicable organs for siRNA drugs. Exp Mol Med 55 1283-92.
3. Akaiwa M Dugal-Tessier J Mendelsohn BA. (2020). Antibody-Drug Conjugate Payloads; Study of Auristatin Derivatives. Chem Pharm Bull (Tokyo) 68 201-11.
4. Autio KA Boni V Humphrey RW Naing A. (2020). Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology. Clin Cancer Res 26 984-9.
5. Bai S Goodrich DW. (2004). Different DNA lesions trigger distinct cell death responses in HCT116 colon carcinoma cells. Mol Cancer Ther 3 613-9.
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Preface for Special Issue: “Emerging strategies, technologies and approaches for the next generation ADCs”;Xenobiotica;2024-07-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3